Mizuho Securities is an investment bank based in Tokyo, Japan, founded in 1917. The firm operates as a financial instruments company, catering to a diverse clientele that includes financial institutions, individuals, and small to medium-sized businesses. Mizuho Securities offers a wide range of services, including equity underwriting, initial public offering consulting, investor relations consulting, bond underwriting, credit rating, and advisory services. By providing these comprehensive financial solutions, Mizuho Securities plays a significant role in the Japanese financial market.
Intel Corporation is a leading technology company founded in 1968, known for its innovation in silicon design, manufacturing, and integrated digital technology platforms. The company plays a pivotal role in advancing computing and communications by providing powerful processors, accelerators, and data-centric solutions that enhance performance, power, and connectivity across a wide range of applications. Intel's commitment to transforming data into actionable insights is evident in its diverse offerings, which include advancements in artificial intelligence, 5G, and autonomous technologies. With a global workforce of approximately 107,000 employees, Intel strives to create transformative products that shape the future of technology and improve everyday life. Through its research arm, Intel Labs, the company continues to pioneer new technologies, ensuring that it remains at the forefront of innovation in the tech industry.
Plus Power
Debt Financing in 2021
Plus Power focuses on the development, ownership, and operation of independent battery energy storage systems. These systems are designed to enhance the flexibility of the electrical grid by providing capacity, energy, and ancillary services. By managing fluctuations in power generation, Plus Power enables the storage of excess energy for later use, helping to integrate renewable energy resources more effectively. The company's technology supports the evolving energy landscape, promoting efficiency and reliability within the grid.
Suono Bio
Series A in 2021
Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, focused on developing innovative therapeutic products utilizing its proprietary delivery technology. Founded in 2016, the company specializes in the ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract, eliminating the need for encapsulation. Suono Bio aims to transform the treatment of challenging diseases, particularly those involving inflammatory-mediated conditions, by enabling efficient and effective delivery of therapeutics across various tissues. This technology has the potential to enhance patient recovery from gastrointestinal diseases by ensuring that treatments reach their intended targets quickly and effectively.
One Tap BUY
Venture Round in 2020
One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in financial application services, focusing on asset management. The company offers a financial smartphone application that enables users to select, buy, and sell stocks with minimal investment amounts. This application provides features that assist users in determining the amounts they wish to trade and allows for day trading. Additionally, it facilitates users in realizing profits by enabling them to buy and sell only profitable stocks while retaining their investments. Formerly known as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015.
PayPay
Venture Round in 2020
PayPay is an online payment application that facilitates mobile transactions for users, allowing them to make payments conveniently. The application is designed to streamline the payment process, making it easier for individuals to manage their financial activities. Users can execute transactions with a limit of 15,000 yen per payment and a maximum monthly limit of 30,000 yen. By focusing on user-friendly features, PayPay aims to enhance the experience of mobile financial management, catering to the growing demand for digital payment solutions.
HiJoJo Partners
Series A in 2020
HiJoJo Partners, Inc. is a venture capital firm established in 2017 and based in Minato, Japan. The company specializes in providing investment opportunities in high-quality middle and late-stage private companies, including unicorns, both domestically and internationally. HiJoJo Partners focuses on direct investments in pre-IPO shares through various financing rounds and secondary markets, catering to the interests of domestic investors seeking access to global large-cap private companies.
One Tap BUY
Corporate Round in 2018
One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in financial application services, focusing on asset management. The company offers a financial smartphone application that enables users to select, buy, and sell stocks with minimal investment amounts. This application provides features that assist users in determining the amounts they wish to trade and allows for day trading. Additionally, it facilitates users in realizing profits by enabling them to buy and sell only profitable stocks while retaining their investments. Formerly known as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015.
Visco Technologies
Post in 2017
Visco Technologies is a manufacturing company specializing in the development, production, sale, and maintenance of machine vision and image processing systems. The company offers a range of services, including visual inspection algorithms and various image processing technologies. Its capabilities encompass alignment, checking, measuring, recognition, and existence verification, aimed at enhancing the efficiency and accuracy of visual inspection processes in various industries.
PayPay
Venture Round in 2017
PayPay is an online payment application that facilitates mobile transactions for users, allowing them to make payments conveniently. The application is designed to streamline the payment process, making it easier for individuals to manage their financial activities. Users can execute transactions with a limit of 15,000 yen per payment and a maximum monthly limit of 30,000 yen. By focusing on user-friendly features, PayPay aims to enhance the experience of mobile financial management, catering to the growing demand for digital payment solutions.
One Tap BUY
Corporate Round in 2017
One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in financial application services, focusing on asset management. The company offers a financial smartphone application that enables users to select, buy, and sell stocks with minimal investment amounts. This application provides features that assist users in determining the amounts they wish to trade and allows for day trading. Additionally, it facilitates users in realizing profits by enabling them to buy and sell only profitable stocks while retaining their investments. Formerly known as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015.
One Tap BUY
Venture Round in 2017
One Tap BUY Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in financial application services, focusing on asset management. The company offers a financial smartphone application that enables users to select, buy, and sell stocks with minimal investment amounts. This application provides features that assist users in determining the amounts they wish to trade and allows for day trading. Additionally, it facilitates users in realizing profits by enabling them to buy and sell only profitable stocks while retaining their investments. Formerly known as My banker Co., Ltd., the company rebranded to One Tap BUY in January 2015.
PayPay
Venture Round in 2017
PayPay is an online payment application that facilitates mobile transactions for users, allowing them to make payments conveniently. The application is designed to streamline the payment process, making it easier for individuals to manage their financial activities. Users can execute transactions with a limit of 15,000 yen per payment and a maximum monthly limit of 30,000 yen. By focusing on user-friendly features, PayPay aims to enhance the experience of mobile financial management, catering to the growing demand for digital payment solutions.
SE Holdings and Incubations
Venture Round in 2010
SE Holdings and Incubations Co., Ltd. is a Japan-based holding company that operates across various business segments. Its Publishing segment focuses on publishing and selling general and computer-related books, providing technical information online, and offering educational conferences. The Corporate Services segment supports product marketing, user assistance, public relations, and investor relations. In the Software Network segment, the company develops and sells entertainment software, offers Internet technologies, maintains cellular phone services, and operates amusement facilities. The Internet Cafe segment manages Internet cafes, while the Education and Personnel segment provides manpower dispatching services. Additionally, the Others segment oversees real estate properties, contributing to the company's diverse portfolio.
Perlegen Sciences
Series D in 2006
Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.
SMS
Venture Round in 2005
SMS is a Japanese company focused on providing information services tailored to the needs of an aging society. The company operates in multiple sectors, including nursing care, medical care, career development, healthcare, senior living, and international services. By catering to both business operators and end users, SMS aims to enhance the information infrastructure necessary for supporting the elderly and those involved in their care. Through its diverse offerings, SMS addresses the unique challenges and requirements of an aging population, facilitating access to essential services and information.
Perlegen Sciences
Series D in 2005
Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.
SourceNext
Venture Round in 2004
SourceNext is a company that specializes in the planning, development, and sales of personal computer software, along with utility software and training products. The firm employs a variety of software development methods, including in-house development and outsourcing, as well as acquiring licenses from other companies for commercialization. SourceNext markets its products through multiple channels, including mobile phone operators, its own online stores, and wholesale distribution to home appliance discount stores and various electronic commerce websites.
MediciNova
Venture Round in 2004
MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, established in 2000. The company specializes in acquiring and developing novel small-molecule therapeutics aimed at treating serious diseases with unmet medical needs, primarily within the United States. MediciNova's product pipeline includes MN-166, an oral anti-inflammatory and neuroprotective agent for neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis; MN-221, a selective beta-2-adrenergic receptor agonist for acute asthma exacerbations; and MN-001, a small molecule for fibrotic diseases like nonalcoholic steatohepatitis. Additionally, MediciNova is involved in the development of MN-029, a tubulin binding agent for solid tumors, and collaborates with BioComo and Mie University on a SARS-CoV-2 vaccine. The company’s strategic alliances, particularly with Japanese pharmaceutical firms, enhance its diversified portfolio of clinical and preclinical candidates, which are characterized by their differentiated therapeutic profiles and significant commercial potential.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.